EUVIMEDObjevte EUVIMED
Crossref

M14 substitutions in exanatide modulate alpha‐synuclein aggregation

Venkataharsha Panuganti, Kanika Manchanda, Prasad V Bharatam, Ipsita Roy iD

The FEBS Journal · 2026

DOI: 10.1111/febs.70321 ↗

At a glance

Journal article in The FEBS Journal, 2026. Written by Venkataharsha Panuganti and 3 co-authors. Institution: Department of Biotechnology, National Institute of Pharmaceutical Education and Research, S.A.S. Nagar, Punjab, India. Major MEDLINE topics: alpha-Synuclein, Exenatide, Protein Aggregates, Peptides. Cited 4 times so far (Crossref); 87 references. Funded by: Science and Engineering Research Board.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Clinical and epidemiological studies suggest similarities in dysregulation of pathways in type 2 diabetes (T2DM) and Parkinson's disease (PD). Efficacy of several antidiabetic drugs has been tested in PD. Exenatide, a synthetic version of exendin‐4, an incretin‐mimetic drug, is an agonist of glucagon‐like peptide 1 receptor (GLP1R) and is approved for the treatment of T2DM. Exenatide can cross the blood–brain barrier and exerts neuroprotective and neurorestorative effects via GLP1R at doses similar to those used in T2DM, resulting in improved motor performance, behaviour, learning and memory in different rodent PD models. Reports in human PD patients have also shown promise. In this work, we carried out substitution at the fourteenth position of exenatide (M14) with basic, acidic and nonpolar residues and investigated their effect on aggregation of recombinant human α‐synuclein in vitro and in SH‐SY5Y cells. Molecular dynamic (MD) simulation studies showed altered stability of α‐synuclein upon substitution at M14 in exenatide. Exenatide had no effect on aggregation of α‐synuclein in vitro . The M14K mutant, which stabilized α‐synuclein, prolonged lag time and caused significant reduction in aggregation. On the contrary, aggregation of α‐synuclein was significantly attenuated in SH‐SY5Y cells in the presence of exenatide for all mutants tested, with a concomitant increase in cell survival. Flow cytometric analysis suggested induction of autophagy in the presence of the peptides, explaining the reduction in protein aggregation. Thus, mutants of exenatide could be investigated further as inhibitors of aggregation of α‐synuclein.

Subjects

MeSH terms (MEDLINE)

alpha-SynucleinExenatideProtein AggregatesPeptidesHypoglycemic AgentsHumansMolecular Dynamics SimulationAmino Acid SubstitutionCell Line, TumorParkinson DiseaseDiabetes Mellitus, Type 2

Author keywords

Parkinson's diseasediabetes mellitusexenatideprotein aggregation

Substances

alpha-SynucleinExenatideProtein AggregatesPeptidesHypoglycemic Agents

Authors and institutions

  • Department of Biotechnology, National Institute of Pharmaceutical Education and Research, S.A.S. Nagar, Punjab, India.
  • Department of Pharmacoinformatics, National Institute of Pharmaceutical Education and Research, S.A.S. Nagar, Punjab, India.
  • Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research, S.A.S. Nagar, Punjab, India.

ORCID profiles: Ipsita Roy

Funding

  • Science and Engineering Research Board

Cite

APA

Panuganti, V., Manchanda, K., Bharatam, P. V., & Roy, I. (2026). M14 substitutions in exanatide modulate alpha‐synuclein aggregation. The FEBS Journal. https://doi.org/10.1111/febs.70321

Vancouver

Panuganti V, Manchanda K, Bharatam PV, Roy I. M14 substitutions in exanatide modulate alpha‐synuclein aggregation. The FEBS Journal. 2026. doi:10.1111/febs.70321

BibTeX
@article{Panuganti2026,
  author = {Panuganti, Venkataharsha and Manchanda, Kanika and Bharatam, Prasad V and Roy, Ipsita},
  title = {M14 substitutions in exanatide modulate alpha‐synuclein aggregation},
  journal = {The FEBS Journal},
  year = {2026},
  doi = {10.1111/febs.70321}
}
Start for free →